Major study finds safer way to give key leukemia drug to kids

NCT ID NCT00400946

Completed Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This study looked at 800 children with acute lymphoblastic leukemia to compare two forms of the drug asparaginase: a pegylated version given through a vein and a standard version given as a shot. The goal was to see which caused fewer serious side effects like allergic reactions, pancreatitis, or blood clots, while still controlling the leukemia. Results help doctors choose the best treatment to keep the disease in check.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia Drug-Related Side Effects and Adverse Reactions leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DRUG/AGENT TOXICITY BY TISSUE/ORGAN LEUKEMIA

Contacts and locations

Locations

Albert Einstein Cancer Center at Albert Einstein College of Medicine

The Bronx, New York, 10461, United States
Centre de Recherche du Centre Hospitalier de l'Universite Laval

Sainte-Foy, Quebec, GIV 4G2, Canada
Dana Farber Cancer Institute

Boston, Massachusetts, 02115, United States
Hasbro Children's Hospital

Providence, Rhode Island, 02903, United States
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center

New York, New York, 10032, United States
Hopital Sainte Justine

Montreal, Quebec, H3T 1C5, Canada
James P. Wilmot Cancer Center at University of Rochester Medical Center

Rochester, New York, 14642, United States
McMaster Children's Hospital at Hamilton Health Sciences

Hamilton, Ontario, L8N 3Z5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.